（ 於開曼群島註冊成立的有限公司） （股份代號：9906） 董事會會議召開日期 宏力醫療管理集團有限公司（「本公司」連同其附屬公司，「本集團」）董事會 （「董事會」）謹此宣佈，本公司將於二零二五年八月二十九日（ 星期五 ）舉行 董事會會議，藉以（ 其中包括 ）考慮及通過本集團截至二零二五年六月三十 日 止六 個月 的中 期業 績及 發佈 ，並 考慮 派發 中期 股息（ 如 有 ），以 及處 理其 他事項。 承董事會命 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Honliv Healthcare Management Group Company Limited 宏 力 醫 療 管 理 集 團 有 限 公 司 董事長 秦岩 香港，二零二五年八月十九日 於 本 公告 日 期 ， 董 事會 成 員 包 ...

Core Viewpoint - Macro Medical Management (09906) anticipates a net loss attributable to shareholders not exceeding RMB 2 million for the six months ending June 30, 2025, compared to a net profit of approximately RMB 20 million for the six months ending June 30, 2024 [1] Group 1 - The expected shift from profit to loss is primarily due to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rate from the public medical insurance plan for the fiscal year 2024, completed in May 2025, was lower than the estimated settlement rate used in the consolidated financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company further adjusted the estimated settlement rate for inpatient service revenue covered by the plan for the first half of 2025 downward due to the aforementioned discrepancies [1]

Core Viewpoint - The company expects to report a net loss attributable to shareholders of no more than RMB 2 million for the six months ending June 30, 2025, a significant decline from a net profit of approximately RMB 20 million for the same period in 2024 [1] Group 1: Financial Performance - The anticipated shift from profit to loss is primarily attributed to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rate from the 2024 public medical insurance plan, completed in May 2025, was lower than the estimated settlement rate used in the financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company has further adjusted the estimated settlement rate for inpatient service revenue covered by the plan for the first half of 2025 downward [1]

Core Viewpoint - The company, Hongli Medical Management, anticipates a net loss attributable to shareholders of no more than RMB 2 million for the six months ending June 30, 2025, a significant decline from a net profit of approximately RMB 20 million for the same period in 2024 [1] Group 1: Financial Performance - The expected shift from profit to loss is primarily attributed to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rates from the public medical insurance plan for the fiscal year 2024, completed in May 2025, were lower than the estimated settlement rates used in the consolidated financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company further adjusted the estimated settlement rates for inpatient service revenue covered by the plan for the first half of 2025 downward due to the aforementioned discrepancies [1]

董事 會認 為上 述預 期由 盈轉 虧的 情況 主要是 由於 (i)住 院醫 療服 務的 需求減 少導致收入減少；及(ii)根據二零二五年五月完成的二零二四年度公共醫療 保 險 計劃 清 算 結 果 ，該 等 實 際 結算 率 低 於 截 至二 零 二 四 年 十二 月 三 十 一日 止 年 度的 綜 合 財 務 報表 所 採 用 的估 計 結 算 率 ，該 等 差 額 導 致本 期 住 院 服務 收 入 減少 ， 以 及 因 此進 一 步 調 低二 零 二 五 年 上半 年 該 計 劃 涵蓋 的 住 院 服務 收入的估計結算率所致。 本 公 司仍 正 落 實 本 集團 本期未 經審 核 綜 合 財 務業 績 。 本 公 告所 載 資 料 僅基 於 本 集團 未 經 審 核 綜合 管 理 賬 目及 董 事 會 目 前可 得 資 料 作 出的 初 步 評 估。 有 關 資料 未 經 本 公 司核 數 師 或 本公 司 審 核 委 員會 審 核 或 審 閱， 故 可 能 會作 出 調 整及 撥 備 。 股 東及 潛 在 投 資者 務 請 細 閱 本集 團 中 期 業 績公 告 ， 有 關公 告預期於二零二五年八月 ...

本月底法定/註冊股本總額： HKD 390,000 公司名稱: 宏力醫療管理集團有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09906 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,900,000,000 | HKD | | 0.0001 | HKD | | 390,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,900,000,000 | HKD | | 0.0001 | HKD | | 390,000 | 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港 ...

Financial Performance - Honliv Healthcare reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the fiscal year 2024[2]. - The company achieved a net profit margin of 10%, translating to a net profit of HKD 120 million for the same period[2]. - Future guidance estimates a revenue growth of 12% for the next fiscal year, projecting revenues of approximately HKD 1.34 billion[2]. - The total comprehensive income for the year ended December 31, 2024, was RMB 768.7 million, an increase of 1.1% compared to RMB 760.5 million for the year ended December 31, 2023[13][21]. - Total revenue for 2024 reached RMB 768.7 million, with treatment and comprehensive medical services accounting for 59.4% and drug sales for 40.2%[32]. - Drug sales revenue grew by 4.7% to RMB 308.9 million in 2024, up from RMB 294.9 million in 2023, primarily due to increased outpatient drug sales[24]. - Outpatient medical service revenue rose by 8.0% from RMB 402.6 million to RMB 434.7 million, driven by an increase in outpatient visits and per-visit costs[33]. - Inpatient medical service revenue decreased by 7.6% from RMB 357.9 million to RMB 330.6 million, primarily due to a reduction in inpatient visits and per-visit costs[33]. - Cost of sales increased by 4.3% from RMB 615.7 million to RMB 642.0 million, mainly due to higher pharmaceutical costs and depreciation[34]. - Gross profit decreased by 12.5% from RMB 144.8 million to RMB 126.7 million, with gross margin declining from 19.0% to 16.5%[35]. - Administrative expenses increased by 5.5% from RMB 72.4 million to RMB 76.4 million, primarily due to higher depreciation and amortization expenses[38]. - Net profit decreased by 18.7% from RMB 38.7 million to RMB 31.5 million, with net profit margin declining from 5.1% to 4.1%[41]. Operational Efficiency - Management highlighted a focus on improving operational efficiency, aiming for a 5% reduction in operational costs by the end of 2025[2]. - The company is focusing on cost control and efficiency improvements, including standardizing clinical pathways and integrating supply chains[25]. - The company aims to optimize patient admission structures based on DRG data to improve cost-effectiveness and resource utilization[25]. - The company is committed to improving operational efficiency and service quality in response to increasing competition and patient demand in the healthcare market[20]. Market Expansion and Strategy - Honliv Healthcare plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share over the next three years[2]. - The company is exploring potential acquisitions to diversify its service offerings, with a budget of HKD 200 million allocated for this purpose[2]. - Future strategies include advancing smart hospital construction and enhancing key specialty development to align with industry trends[30]. - The company aims to leverage technological breakthroughs and innovative models to drive growth in the evolving Chinese healthcare market[15]. - The company is responding to the dual pressures of policy reform and demand upgrades by enhancing its competitiveness through specialization, service innovation, and technological breakthroughs[20]. Patient and Service Metrics - User data indicated a growth in active patients by 20%, totaling 150,000 active patients by the end of 2024[2]. - The total number of inpatient visits was 52,940, a decrease of 3.4% from 54,795 in the previous year[22]. - The total number of outpatient visits increased by 2.8% to 1,440,183 from 1,400,791 in the previous year[22]. - Outpatient visits increased by 2.8% to 1,440,183 in 2024, while inpatient visits decreased by 3.4% to 52,940[23]. - The company has launched a new telehealth service, expecting to attract an additional 30,000 users within the first year[2]. Governance and Compliance - Honliv Healthcare's board of directors emphasized the importance of corporate governance and compliance with the latest regulations to maintain investor confidence[2]. - The group emphasizes compliance with regulatory requirements and continues to strengthen internal control compliance management[80]. - The company has established a compliant pollutant control system to meet relevant legal requirements regarding environmental protection[74]. - The company has adopted a standard code of conduct for securities trading by directors[170]. Employee and Shareholder Information - The total number of full-time employees as of December 31, 2024, was 1,955, a decrease from 1,969 employees as of December 31, 2023[65]. - Employee costs for the fiscal year 2024 were approximately RMB 210.9 million, compared to RMB 217.5 million for the fiscal year 2023[65]. - The company raised approximately HKD 264.8 million from the global offering by issuing 150,000,000 shares at HKD 2.10 per share[67]. - As of December 31, 2024, the unutilized net proceeds from the global offering amounted to HKD 69.2 million[68]. - The group did not recommend the distribution of a final dividend for the year ending December 31, 2024[82]. Share Option and Incentive Plans - The company has a share option plan approved on June 17, 2020, which is valid for ten years[119]. - The share option plan allows the company to grant options to selected participants as an incentive for their contributions[120]. - The maximum number of shares that can be issued under the share option plan is capped at 30% of the company's issued share capital[124]. - The general limit for shares that can be issued under the share option plan is set at 10%, equivalent to 60,000,000 shares[124]. - The company adopted the 2022 Restricted Share Unit Plan on August 22, 2022, to recognize and incentivize participants for their contributions[134]. - The 2023 Restricted Share Unit Plan was adopted on May 9, 2023, aimed at recognizing and incentivizing employees of acquired entities[147]. Financial Position and Cash Flow - Cash and cash equivalents increased to approximately RMB 258.5 million from RMB 239.8 million, with bank loans slightly decreasing from RMB 138.0 million to RMB 137.0 million[42]. - The net cash used in investing activities decreased from RMB 88.8 million for the year ended December 31, 2023, to RMB 51.4 million for the year ending December 31, 2024, primarily due to a reduction in expenditures for updating facilities and purchasing equipment by RMB 37.4 million[55]. - The net cash used in financing activities decreased from RMB 19.1 million for the year ended December 31, 2023, to RMB 13.3 million for the year ending December 31, 2024, mainly due to new borrowings of RMB 156.7 million and repayments of borrowings and related interest of RMB 168.4 million[56]. - As of December 31, 2024, the debt-to-asset ratio was 40.6%, down from 43.5% as of December 31, 2023[59]. Audit and Governance Structure - The independent auditor for the year ending December 31, 2024, was PwC, with total fees amounting to RMB 1.95 million[181]. - The audit committee consists of three independent non-executive directors as of the date of the report[165]. - The company has established a remuneration committee responsible for evaluating the performance of directors and senior management, which includes three independent non-executive directors[166]. - The company has a nomination committee that includes one executive director and three independent non-executive directors, responsible for identifying candidates for the board and senior management[167].

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 768,725,000, representing a 1.1% increase from RMB 760,527,000 in 2023[2] - Gross profit decreased by 12.5% to RMB 126,692,000 from RMB 144,844,000 in the previous year[2] - Profit attributable to owners of the company was RMB 31,151,000, down 18.7% from RMB 38,310,000 in 2023[2] - Basic and diluted earnings per share decreased by 14.3% to RMB 0.06 from RMB 0.07[2] - Operating profit for the year was RMB 50,421,000, a decline from RMB 57,445,000 in 2023[4] - The net profit attributable to the company's owners for the year ended December 31, 2024, was RMB 31,151 thousand, down from RMB 38,310 thousand in 2023, a decrease of about 18.5%[22] - Basic earnings per share for 2024 was RMB 0.06, compared to RMB 0.07 in 2023, representing a decline of approximately 14.3%[22] - Net profit decreased by 18.7% from RMB 38.7 million in 2023 to RMB 31.5 million in 2024, resulting in net profit margins of 5.1% and 4.2% respectively[55] Revenue Breakdown - Revenue from medical services was RMB 456,442 thousand in 2024, slightly down from RMB 465,598 thousand in 2023, indicating a decrease of about 3.3%[20] - Pharmaceutical sales increased to RMB 308,861 thousand in 2024 from RMB 294,929 thousand in 2023, reflecting a growth of approximately 4.7%[20] - Outpatient medical service revenue rose by 8.0% from RMB 402.6 million in 2023 to RMB 434.7 million in 2024, driven by an increase in outpatient patient visits and average fees[48] - Inpatient medical service revenue decreased by 7.6% from RMB 357.9 million in 2023 to RMB 330.6 million in 2024, attributed to a decline in inpatient patient visits and average fees[48] Assets and Liabilities - Total assets increased slightly to RMB 974,003,000 from RMB 968,709,000[10] - Total liabilities decreased to RMB 395,080,000 from RMB 421,262,000[10] - Current liabilities decreased to RMB 380,403,000 from RMB 395,465,000[10] - The group's total liabilities decreased to RMB 100,666 thousand in 2024 from RMB 124,461 thousand in 2023, a reduction of approximately 19.1%[26] - The company's debt-to-asset ratio as of December 31, 2024, was 40.6%, down from 43.5% as of December 31, 2023[72] Cash Flow - The net cash generated from operating activities decreased from RMB 91.6 million for the year ended December 31, 2023, to RMB 83.3 million for the year ended December 31, 2024, primarily due to slower collection of receivables from the medical insurance bureau[67] - The net cash used in investing activities decreased from RMB 88.8 million for the year ended December 31, 2023, to RMB 51.4 million for the year ended December 31, 2024, mainly due to a reduction in expenditures for facility upgrades and equipment purchases by RMB 37.4 million[68] - The net cash used in financing activities decreased from RMB 19.1 million for the year ended December 31, 2023, to RMB 13.3 million for the year ended December 31, 2024, due to new borrowings of RMB 156.7 million and repayments of borrowings and related interest totaling RMB 168.4 million[69] Operational Metrics - Total inpatient visits decreased by 3.4% to 52,940 for the year ending December 31, 2024, compared to 54,795 for the previous year[34] - The number of outpatient visits increased by 2.8% to 1,440,183 for the year ending December 31, 2024, compared to 1,400,791 for the previous year[35] - Outpatient average cost increased by 5.0% to RMB 301.9 for the year ending December 31, 2024, compared to RMB 287.4 for the previous year[34] - The average length of hospital stay increased by 2.0% to 9.5 days for the year ending December 31, 2024, compared to 9.3 days for the previous year[35] Corporate Governance - The company has adopted corporate governance codes and complied with all applicable provisions, except for the separation of roles between the Chairman and CEO as stipulated in the corporate governance code[78] - The company has appointed Mr. Qin Yan as both Chairman and CEO, believing his leadership will effectively guide business decisions and strategies[79] - The Audit Committee, consisting of three independent non-executive directors, has reviewed the consolidated financial statements for the year ending December 31, 2024, and found them to be prepared in accordance with applicable accounting standards[81] - The company has adopted a standard code of conduct for directors regarding securities trading, which has been confirmed as adhered to by all directors during the reporting period[80] - The company has made changes to the Nomination Committee to enhance corporate governance and meet new gender diversity requirements effective July 1, 2025[88] Future Plans and Strategies - The company is focusing on enhancing competitiveness through specialized services, service innovation, and technological breakthroughs in response to market pressures and opportunities[31] - Future plans include advancing tiered evaluation, smart hospital construction, and specialized treatment center development[42] - The company aims to strengthen cost control and risk management in response to DRG/DIP medical insurance payment policies[45] - The company is adapting to changes in the economic environment by optimizing cost structures and improving treatment efficiency[30] Social Responsibility - The company actively engages in social responsibility initiatives, including free lung nodule screening activities[41] - The company focuses on integrating medical resources and enhancing collaborative development for sustainable growth[45] Shareholder Information - The company has not declared any dividends for the year ending December 31, 2024[27] - The company will not recommend the payment of a final dividend for the year ending December 31, 2024[84] - The annual performance announcement will be published on the company's website and the Hong Kong Stock Exchange website, with the annual report to be sent to shareholders in due course[85] - The company will hold its annual general meeting on June 13, 2025, with details to be provided to shareholders[86] - The company will suspend the registration of share transfers from June 10, 2025, to June 13, 2025, to determine eligibility for attending the annual general meeting[87] Miscellaneous - The company has not engaged in any purchases, sales, or redemptions of its listed securities during the year ended December 31, 2024[76] - There were no significant events occurring after the reporting period as of the announcement date[77] - The company has obtained 60 scientific and technological achievements, including practical information management systems[40] - The company's auditor, PwC, has confirmed that the figures in the consolidated financial statements are consistent with the audited financial statements for the year[82] - The reporting period ends on December 31, 2024, as per the company's announcement[94] - The company has adopted a restricted share unit plan on May 9, 2023, to incentivize performance among directors[94]

Financial Performance - Honliv Healthcare reported a revenue increase of 15% year-over-year for the first half of 2024, reaching HKD 500 million[2]. - The group's consolidated revenue for the first half of 2024 was RMB 415.2 million, an increase of RMB 44.7 million or 12.1% compared to RMB 370.5 million for the same period in 2023[6]. - The company reported a net profit of HKD 80 million, representing a 12% increase compared to the same period last year[2]. - The net profit for the six months ended June 30, 2024, decreased by 17.3% to RMB 20.3 million, with a net profit margin of 4.9%[30]. - The company reported a revenue of RMB 415,178,000 for the six months ended June 30, 2024, representing a 12.0% increase from RMB 370,467,000 in the same period of 2023[87]. - The net profit attributable to equity holders was RMB 20,042,000, a decrease of 17.0% compared to RMB 24,263,000 in the prior year[90]. Patient Services and Growth - The number of patients treated at Honliv Healthcare facilities grew by 20%, totaling 150,000 patients in the reporting period[2]. - The company plans to expand its services to three new locations in China by the end of 2024, aiming for a 25% increase in patient capacity[2]. - Honliv Healthcare has launched a new telemedicine service, expecting to attract an additional 10,000 patients by the end of the year[2]. - Revenue from outpatient medical services increased by 16.3% to RMB 224.9 million, driven by an increase in patient visits and average outpatient fees[24]. - Revenue from inpatient medical services rose by 7.3% to RMB 189.9 million, primarily due to an increase in inpatient visits[24]. Cost Management and Profitability - The gross profit margin improved to 35%, up from 30% in the previous year, indicating better cost management[2]. - Gross profit for the six months ended June 30, 2024, was RMB 71.6 million, a 2.4% increase from RMB 70.0 million in the same period of 2023, with a gross margin decrease from 18.9% to 17.3%[26]. - Total sales costs increased by 14.3% to RMB 343.6 million, mainly due to higher drug costs and employee benefits[25]. - The average cost per inpatient was RMB 6,498.2, up 1.4% from RMB 6,409.5 in the previous year[11]. - The average cost per outpatient was RMB 300.4, representing a 9.8% increase from RMB 273.6[13]. Investments and Technology - Honliv Healthcare is investing HKD 50 million in new medical technology and equipment to enhance service quality and operational efficiency[2]. - The group plans to enhance smart hospital construction and improve medical service capabilities while leveraging digital healthcare technologies[5]. - The company is exploring potential acquisition opportunities to strengthen its market position in the healthcare sector[2]. Corporate Governance and Compliance - Honliv Healthcare is committed to enhancing its corporate governance practices in line with the latest regulatory requirements[2]. - The company has complied with all applicable corporate governance codes during the reporting period, except for the separation of roles between the Chairman and CEO[80]. Shareholder Information and Stock Options - As of June 30, 2024, the company has issued 600,000,000 shares[50]. - Major shareholders include Cao Jianming with 443,983,500 shares (74.00%) and Rubrical Investment with 133,195,050 shares (22.20%)[49]. - The company has a stock option plan approved on June 17, 2020, valid for ten years[52]. - The stock option plan aims to incentivize selected participants for their contributions to the company[53]. - The total number of shares that may be issued under the stock option plan cannot exceed 30% of the company's issued share capital[55]. Cash Flow and Financial Position - Net cash generated from operating activities increased from RMB 46.4 million for the six months ended June 30, 2023, to RMB 57.3 million for the six months ended June 30, 2024, attributed to increased operating profit[40]. - The company's debt-to-asset ratio as of June 30, 2024, was 42.8%, a slight decrease from 43.5% as of December 31, 2023[45]. - The company secured an additional loan facility of RMB 60 million from a bank, which can be drawn until March 5, 2025, but has not yet utilized this facility[95]. - The company’s current liabilities exceeded its current assets by RMB 42,855,000 as of June 30, 2024[95]. - Management believes that the company will have sufficient financial resources to support operations and meet financial obligations due within the next twelve months[96]. Employee and Operational Metrics - Employee costs for the six months ended June 30, 2024, amounted to RMB 118.1 million, an increase from RMB 107.4 million for the same period in 2023[84]. - The total number of employees as of June 30, 2024, was approximately 1,953, up from 1,886 a year earlier[84]. - Total compensation for key management personnel for the six months ended June 30, 2024, was RMB 2,072,000, a slight increase from RMB 2,054,000 in the same period of 2023[140]. Related Party Transactions - The company provided free parking spaces to Henan Hongli General Aviation Co., Ltd. for the six months ended June 30, 2024, and June 30, 2023[136]. - Rental income from related parties for the six months ended June 30, 2024, was RMB 138,000, a decrease of 30.3% from RMB 198,000 for the same period in 2023[137]. - The company’s related party transactions are conducted in the ordinary course of business based on negotiated terms[135].

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 415,178, an increase of 12.1% compared to RMB 370,467 for the same period in 2023[1] - Gross profit for the same period was RMB 71,621, reflecting a 2.4% increase from RMB 69,950 in 2023[1] - Profit attributable to owners of the company decreased by 17.4% to RMB 20,042 from RMB 24,263 in the prior year[1] - Basic and diluted earnings per share remained unchanged at RMB 0.04 for both periods[3] - Operating profit for the six months was RMB 31,833, down from RMB 33,683 in the previous year[2] - The net profit attributable to the company's owners for the six months ended June 30, 2024, was RMB 20,042,000, down from RMB 24,263,000 in the same period of 2023[16] - Net profit decreased by 17.3% from RMB 24.5 million for the six months ended June 30, 2023, to RMB 20.3 million for the six months ended June 30, 2024, with net profit margin at 6.6% and 4.9% respectively[40] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 992,674, compared to RMB 968,709 as of December 31, 2023[4] - Total equity increased to RMB 567,710 from RMB 547,447 at the end of the previous year[5] - Non-current assets totaled RMB 627,045, slightly down from RMB 632,979 at the end of 2023[4] - Current assets increased to RMB 365,629 from RMB 335,730 at the end of the previous year[4] - As of June 30, 2024, the group's current liabilities exceeded its current assets by RMB 42,855,000, with cash and cash equivalents amounting to RMB 260,203,000[8] - Trade payables increased to RMB 125.676 million as of June 30, 2024, compared to RMB 94.461 million as of December 31, 2023[21] - Trade receivables as of June 30, 2024, amounted to RMB 99,344,000, with a provision for impairment of RMB 22,336,000, resulting in a net value of RMB 77,008,000[19] - Trade receivables increased by 143.3% from RMB 31.6 million as of December 31, 2023, to RMB 77.0 million as of June 30, 2024[42] - Inventory decreased by 35.0% from RMB 31.9 million as of December 31, 2023, to RMB 20.7 million as of June 30, 2024[41] Revenue Breakdown - Revenue from medical and comprehensive healthcare services was RMB 250,041,000, up from RMB 228,587,000, representing a growth of 9.3%[12] - Pharmaceutical sales increased to RMB 164,739,000 from RMB 141,880,000, reflecting a growth of 16.1%[12] - Total revenue from treatment and comprehensive medical services, pharmaceutical sales, and postpartum care services rose by 12.1% to RMB 415.2 million from RMB 370.5 million[32] - The revenue from outpatient medical services accounted for 54.2% of total revenue, increasing from 52.2% in the previous year[31] - Outpatient medical service revenue increased by 16.3% from RMB 193.4 million for the six months ended June 30, 2023, to RMB 224.9 million for the six months ending June 30, 2024[33] - Inpatient medical service revenue rose by 7.3% from RMB 177.0 million for the six months ended June 30, 2023, to RMB 189.9 million for the six months ending June 30, 2024[33] Operational Metrics - The number of emergency and outpatient visits for the six months ended June 30, 2024, was 748,721, up 5.9% from 707,008 for the same period in 2023[24] - The number of inpatient visits for the six months ended June 30, 2024, was 29,218, an increase of 5.8% from 27,620 for the same period in 2023[24] - Total inpatient visits reached 29,218, an increase of 5.8% compared to 27,620 in the same period last year[25] - Average inpatient cost per visit was RMB 6,498.2, up 1.4% from RMB 6,409.5 in the previous year[25] - Outpatient visits totaled 748,721, reflecting a growth of 5.9% from 707,008 in the same period last year[25] - Average outpatient cost per visit increased by 9.8% to RMB 300.4 from RMB 273.6[25] - The number of operating beds remained stable at 1,500, with an average length of stay of 8.8 days, down 1.1% from 8.9 days[25] Cash Flow and Financing - Cash generated from operating activities was RMB 57.3 million for the six months ending June 30, 2024, compared to RMB 46.4 million for the same period in 2023[49] - Operating cash flow increased from RMB 46.4 million for the six months ended June 30, 2023, to RMB 57.3 million for the six months ended June 30, 2024, primarily due to increased operating profit[50] - Net cash used in investing activities decreased from RMB 37.8 million for the six months ended June 30, 2023, to RMB 23.0 million for the six months ended June 30, 2024, mainly due to reduced payments for the purchase of property, plant, and equipment by RMB 16.0 million[51] - Financing activities generated cash flow of RMB 9.5 million for the six months ended June 30, 2023, while cash used in financing activities was RMB 14.0 million for the six months ended June 30, 2024, primarily due to repayment of loans amounting to RMB 8.9 million[52] - The company's debt-to-asset ratio was 42.8% as of June 30, 2024, compared to 43.5% as of December 31, 2023[55] Strategic Initiatives - The company aims to promote the construction of smart hospitals and enhance medical service capabilities[23] - The company plans to explore new medical models and leverage policy benefits to align with national healthcare reforms[23] - The company is focused on improving medical quality and safety while expanding its business scale through various investment strategies[23] - The group is actively expanding service areas and enhancing patient experience through smart hospital initiatives and quality control activities[26] - The group published 22 medical research papers and received 6 provincial-level technology achievement certificates in the first half of 2024[29] Employee and Governance - The total number of employees as of June 30, 2024, is approximately 1,953, an increase from 1,886 as of June 30, 2023[65] - Employee costs for the six months ended June 30, 2024, amounted to approximately RMB 118.1 million, compared to RMB 107.4 million for the same period in 2023, reflecting an increase of about 10.5%[65] - The board of directors includes three independent non-executive directors, ensuring governance and oversight[63] - The audit committee has reviewed the unaudited interim results for the six months ended June 30, 2024, and believes they are prepared in accordance with applicable accounting standards[63] - The independent auditor has conducted a review of the interim financial information for the reporting period[63] Dividend and Share Capital - The company did not declare an interim dividend for the six months ended June 30, 2024[22] - The company does not recommend the payment of any interim dividend for the six months ended June 30, 2024[64] - The company has maintained at least 25% of its total issued share capital held by the public as of the announcement date[59] Post-Reporting Events - No significant events occurred after the reporting period as of the announcement date[60] - The interim results announcement is available on the Hong Kong Stock Exchange website and the company's website[67] - The company expresses gratitude to its management team and employees for their contributions to the group's success[68] Use of Proceeds - The net proceeds from the global offering amounted to approximately HKD 264.8 million, after deducting related underwriting fees and expenses[56] - As of June 30, 2024, the company had utilized HKD 195.6 million of the net proceeds from the global offering, with HKD 69.2 million remaining unutilized[57] - 29.5% of the net proceeds from the global offering is allocated for the expansion of the company's Phase I building, with an amount of HKD 78.0 million fully utilized[57] - 26.1% of the net proceeds is designated for funding the acquisition of hospitals to expand the company, with HKD 69.2 million yet to be utilized[57]